The antiatherogenic function of HDL is impaired in hyperhomocysteinemic subjects

Journal of Nutrition

Volumn 138, Issue 11, 2008, Pages 2070-2075

  Holven, Kirsten B ^a,b,c   Aukrust, Pål ^b,c   Retterstøl, Kjetil ^b   Otterdal, Kari ^c   Bjerkeli, Vigdis ^c   Ose, Leiv ^b   Nenseter, Marit S ^b,c   Halvorsen, Bente ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE; CHOLESTEROL; FOLIC ACID; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DISEASE SEVERITY; DRUG INHIBITION; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HYPERHOMOCYSTEINEMIA; MACROPHAGE; MALE; ONCOGENE; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN ISOLATION; UMBILICAL VEIN;

ADULT; AGED; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CELLS, CULTURED; CHOLESTEROL; CHOLESTEROL, HDL; CYTOKINES; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYPERHOMOCYSTEINEMIA; INFLAMMATION; MACROPHAGES; MALE; MIDDLE AGED;

EID: 55949098518     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.108.090704     Document Type: Article

References (27)

1. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325:1202-6.
2. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015-22.
3. Bautista LE, Arenas IA, Penuela A, Martinez LX. Total plasma homocysteine level and risk of cardiovascular disease: a meta-analysis of prospective cohort studies. J Clin Epidemiol. 2002;55:882-7.
4. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565-75.
5. Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578-88.
6. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567-77.
7. Sweetnam PM, Bolton CH, Yarnell JWG, Bainton D, Baker IA, Elwood PC, Miller NE. Associations of the Hdl(2)-cholesterol and Hdl(3)-cholesterol subfractions with the development of ischemic-heart-disease in british men: the Caerphilly and Speedwell Collaborative Heart-Disease Studies. Circulation. 1994;90:769-74.
8. Yu S, Yarnell JW, Sweetnam P, Bolton CH. High density lipoprotein subfractions and the risk of coronary heart disease: 9-years follow-up in the Caerphilly Study. Atherosclerosis. 2003;166:331-8.
9. Jacobs DR Jr, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA. High-density cholesterol as a predictor of cardiovascular disease mortality in men and women:the follow-up study of the lipid research clinics prevalence study. Am J Epidemiol. 1990;131:32-47.
10. Franceschini G, Siertori CR. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest. 1980;66:892-900. 11. Nobecourt E, Davies MJ, Brown BE, Curtiss LK, Bonnet DJ, Charlton F, Januszewski AS, Jenkins AJ, Barter PJ, et al. The impact of glycation on apo A-1 structure and its ability to activate lecithin:cholesterol acyltransferase. DIABETOLOGIA. 2007;50:643-53.
11. Ferretti G, Bacchetti T, Marotti E, Curatola G. Effect of homocysteinylation on human high-density lipoproteins: a correction with paraoxonase activity. Metabolism. 2003;52:146-51.
12. Navab M, Anantharamaiah GM, Reddy ST, van Lenten BJ, Ansell BJ, Folgelman AM. Mechanisms of disease: proatherogenic HDL-an evolving field. Nat Clin Pract Endocrinol Metab. 2006;2:504-11.
13. Holven KB, Aukrust P, Holm T, Ose L, Nenseter MS. Folic acid treatment reduces chemokine release from peripheral blood mononuclear cells in hyperhomocysteinemic subjects. Arterioscler Thromb Vasc Biol. 2002;22:699-703.
14. Holven KB, Aukrust P, Pedersen TM, Ose L, Nenseter MS. Enhanced platelet activation in hyperhomocysteinemic individuals. J Thromb Haemost. 2007;5:193-5.
15. Holven KB, Aukrust P, Retterstøl K, Hagve TA, Mørkrid L, Ose L, Nenseter MS. Increased levels of high-sensitivity C-reactive protein and interleukin-6 in hyperhomocysteinemic subjects. Scand J Clin Lab Invest. 2006;66:45-54.
16. 3 from patients with familial hypercholesterolemia are less able to inhibit cytokine release and to promote cholesterol efflux. J Nutr. 2006;136:877-81.
17. Balstad TR, Holven KB, Ottestad IO, Otterdal K, Halvorsen B, Myhre AM, Ose L, og Nenseter MS. Altered composition of HDL(3) in FH subjects causing a HDL subfraction with less atheroprotective function. Clin Chim Acta. 2005;359:171-8.
18. Rosenblat M, Vaya J, Shih D, Aviram M. Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis. 2005;179:69-77.
19. Poulakou MV, Paraskevas KI, Vlachos IS, Karabina SA, Wilson MR, Iliopoulos DC, Tsitsilonis SI, Mikhailidis DP, Perrea DN. Effect of statins on serum apolipoprotein j and paraoxonase-1 levels in patients with ischemic heart disease undergoing coronary angiography. Angiology. 2008;59:137-44.
20. Kural BV, Orem C, Uydu HA, Alver A, Orem A. The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia. Coron Artery Dis. 2004;15:277-83.
21. Paragh G, Törocsik D, Seres I, Harangi M, Illyés L, Balogh Z, Kovács P. Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia. Curr Med Res Opin. 2004;20:1321-7.
22. Mikael LG, Genest J Jr, Rozen R. Elevated homocysteine reduces apolipoprotein A-1 expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ Res. 2006;98:564-71.
23. Liao D, Tan H, Hui R, Li Z, Jiang X, Gaubatz J, Yang F, Durante W, Chan L, et al. Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-1 protein synthesis and enhancing HDL cholesterol clearance. Circ Res. 2006;99:598-606.
24. Ansell BJ, Fonarow GC, Fogelman AM. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol. 2007;18:427-34.
25. Lakshman MR, Gottipati CS, Narasimhan SJ, Munoz J, Marmillot P, Nylen ES. Inverse correlation of serum paraoxonase and homocysteine thiolactonase activities and antioxidant capacity of high-density lipoprotein with the severity of cardiovascular disease in persons with type 2 diabetes mellitus. Metabolism. 2006;55:1201-6.
26. Lacinski M, Skorupski W, Cieslinski A, Sokolowska J, Trzeciak WH, Jakubowski H. Determinants of homocysteine-thiolactonase activity of the paraoxonase-1 (PON1) protein in humans. Cell Mol Biol (Noisy-le-grand). 2004;50:885-93.
27. Kerkeni M, Addad F, Chauffert M, Chuniaud L, Miled A, Trivin F, Maaroufi K. Hyperhomocysteinemia, paraoxonase activity and risk of coronary disease. Clin Biochem. 2006;39:821-5.